Summary
We seem to be trading in a narrow range this week with a break possible in either direction.
Why did Gilead sign a multibillion-dollar deal for zinc finger genomic editing technology and not CRISPR/Cas9?
We discuss some possible reasons why Gilead may have opted for Zinc finger technology.
We seem to be trading in a narrow range this week with a break possible in either direction. Hopefully, tomorrow we will get some more insight on the future direction.
Advances: declines= 42%: 49.2%.
A key question that arises is why Gilead (GILD) signed a multi-billion-dollar deal with Sangamo (SGMO) whose zinc finger genomic editing technology has been called ‘old’ and ‘outdated.’ The reason could be well explained in an excellent review article here.
